Skip to content

Antiviral development is critical for pandemic preparedness

Before covid-19 burst into our lives and onto our screens in 2019, the word ‘pandemic’ was not part of the daily vocabulary. It’s quite possible that I’ve never even used the word during my 46 years on this planet. Now,…

Kimer Med wins Innovative Business Award

We were  honoured to be recognised for our innovative business model, and our approach to antiviral development at the Nelson Tasman Chamber of Commerce Business Awards. It was a great way to raise the profile of our business.   Nelson…

Q&A – All your antiviral questions and answers

In this article we will answer some of the questions we get asked about our work. If you have a question you’d like answered, please email us. The most recent updates are  added to the bottom of the article, and…

Biotech firm to expand its antiviral drug research in Nelson

Media Release – 28 November 2022 Nelson biotech company Kimer Med is expanding into a new laboratory and looking to hire additional staff after signing an agreement with Cawthron Institute this week. The move means Kimer Med will now be…

A cure for Monkeypox – is re-purposing existing drugs the way to go?

The current monkeypox outbreak continues to cause concern, not least because there are no specific antivirals to treat this infection. As attention turns to rapidly repurposing other drugs in the hope that they might prove to be effective, the situation…

A new virus has recently been discovered in China. Should we be alarmed?

An international team of scientists is now monitoring a newly-identified and potentially dangerous virus that is believed to have ‘jumped’ from animals to humans. You may recall that SARS-CoV-2, the virus that causes COVID-19, spilled over from bats into the…

Back To Top